文献速递胸部肿瘤

度伐利尤单抗联合或不联合替西木单抗联合化疗一线治疗转移性非小细胞肺癌:III期POSEIDON研究

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
PubMed 文献 · J Clin Oncol · 2022-11-03

POSEIDON研究为开放标签III期试验,纳入1013例EGFR/ALK野生型转移性非小细胞肺癌患者,随机接受替西木单抗+度伐利尤单抗+化疗(T+D+CT)、度伐利尤单抗+化疗(D+CT)或单纯化疗(CT)。D+CT较CT显著改善无进展生存期(HR 0.74),总生存期有改善趋势但未达统计学显著(HR 0.86,P=0.0758);T+D+CT较CT显著改善无进展生存期(HR 0.72)和总生存期(HR 0.77)。

要点

  • D+CT较CT显著改善无进展生存期(HR 0.74,P=0.0009),总生存期未达统计学显著(HR 0.86,P=0.0758)。
  • T+D+CT较CT显著改善无进展生存期(HR 0.72,P=0.0003)和总生存期(HR 0.77,P=0.0030)。
  • T+D+CT、D+CT和CT的3/4级治疗相关不良事件发生率分别为51.8%、44.6%和44.4%。

核心结论

  • D+CT较CT显著改善无进展生存期;在度伐利尤单抗联合化疗基础上加用有限疗程的替西木单抗较CT显著改善总生存期和无进展生存期,且未带来有意义的额外耐受性负担,代表一线转移性非小细胞肺癌的潜在新选择。

研究设计与样本

  • 开放标签III期POSEIDON研究,纳入1013例EGFR/ALK野生型转移性非小细胞肺癌患者,按1:1:1随机分配至T+D+CT组、D+CT组或CT组。
  • T+D+CT组:替西木单抗75 mg+度伐利尤单抗1500 mg+铂类化疗最多4个21天周期,随后度伐利尤单抗每4周一次直至进展,并追加一次替西木单抗。
  • D+CT组:度伐利尤单抗+化疗最多4个21天周期,随后度伐利尤单抗每4周一次直至进展。
  • CT组:化疗最多6个21天周期(所有组均可联合或不联合培美曲塞维持治疗)。
  • 主要终点为D+CT对比CT的无进展生存期和总生存期;关键α控制次要终点为T+D+CT对比CT的无进展生存期和总生存期。

主要发现

  • D+CT组对比CT组:无进展生存期显著改善(HR 0.74,95%CI 0.62-0.89,P=0.0009;中位5.5 vs 4.8个月);总生存期改善趋势未达统计学显著(HR 0.86,95%CI 0.72-1.02,P=0.0758;中位13.3 vs 11.7个月;24个月总生存率29.6% vs 22.1%)。
  • T+D+CT组对比CT组:无进展生存期显著改善(HR 0.72,95%CI 0.60-0.86,P=0.0003;中位6.2 vs 4.8个月);总生存期显著改善(HR 0.77,95%CI 0.65-0.92,P=0.0030;中位14.0 vs 11.7个月;24个月总生存率32.9% vs 22.1%)。
  • 治疗相关不良事件最高为3/4级者:T+D+CT组51.8%、D+CT组44.6%、CT组44.4%;因治疗相关不良事件终止治疗者分别为15.5%、14.1%和9.9%。

临床怎么用

  • 原文结论指出,D+CT较CT显著改善无进展生存期,加用有限疗程替西木单抗的T+D+CT较CT显著改善总生存期和无进展生存期,代表一线转移性非小细胞肺癌的潜在新选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC). METHODS: Patients (n = 1,013) with EGFR/ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalumab 1,500 mg and platinum-based chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression and one additional tremelimumab dose; durvalumab plus chemotherapy for up to four 21-day cycles, followed by durvalumab once every 4 weeks until progression; or chemotherapy for up to six 21-day cycles (with or without maintenance pemetrexed; all arms). Primary end points were progression-free survival (PFS) and overall survival (OS) for D + CT versus CT. Key alpha-controlled secondary end points were PFS and OS for T + D + CT versus CT. RESULTS: PFS was significantly improved with D + CT versus CT (hazard ratio [HR], 0.74; 95% CI, 0.62 to 0.89; P = .0009; median, 5.5 v 4.8 months); a trend for improved OS did not reach statistical significance (HR, 0.86; 95% CI, 0.72 to 1.02; P = .0758; median, 13.3 v 11.7 months; 24-month OS, 29.6% v 22.1%). PFS (HR, 0.72; 95% CI, 0.60 to 0.86; P = .0003; median, 6.2 v 4.8 months) and OS (HR, 0.77; 95% CI, 0.65 to 0.92; P = .0030; median, 14.0 v 11.7 months; 24-month OS, 32.9% v 22.1%) were significantly improved with T + D + CT versus CT. Treatment-related adverse events were maximum grade 3/4 in 51.8%, 44.6%, and 44.4% of patients receiving T + D + CT, D + CT, and CT, respectively; 15.5%, 14.1%, and 9.9%, respectively, discontinued treatment because of treatment-related adverse events. CONCLUSION: D + CT significantly improved PFS versus CT. A limited course of tremelimumab added to durvalumab and chemotherapy significantly improved OS and PFS versus CT, without meaningful additional tolerability burden, representing a potential new option in first-line mNSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Johnson ML, Cho BC, Luft A, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2022. PMID: 36327426. doi:10.1200/JCO.22.00975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。